J. Mataraza

发表

Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing

T. Chiles, Z. Qin, Zhongping Huang, 2005, Nature Methods.

Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth.

T. Chiles, J. Mataraza, Cheryl A. Doughty, 2006, Blood.

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

J. Schellens, Sunil Sharma, A. Naing, 2020, Journal for ImmunoTherapy of Cancer.

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Matthew D. Shirley, Hao Wang, P. Hammerman, 2021, Cancer Research.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Angad P. Singh, A. Singh, A. Lesokhin, 2021, Journal for ImmunoTherapy of Cancer.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer.

P. Ascierto, A. Fasolo, J. Mataraza, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Disruption of Cyclin D3 Blocks Proliferation of Normal B-1a Cells, but Loss of Cyclin D3 Is Compensated by Cyclin D2 in Cyclin D3-Deficient Mice1

Sean M. Gurdak, Maria R. Gumina, T. Chiles, 2006, The Journal of Immunology.

D 3-Deficient Mice Is Compensated by Cyclin D 2 in Cyclin of Normal B-1 a Cells , but Loss of Cyclin D 3 Disruption of Cyclin D 3 Blocks Proliferation

Sean M. Gurdak, Maria R. Gumina, Chiles, 2006 .

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Sung-Bae Kim, R. Greil, S. Kuemmel, 2021, Clinical Cancer Research.

Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

F. Hodi, Y. Bang, H. Joensuu, 2018 .

IQGAP1 Stimulates Proliferation and Enhances Tumorigenesis of Human Breast Epithelial Cells*

David B Sacks, Ha-won Jeong, D. Sacks, 2008, Journal of Biological Chemistry.

IQGAP1 Promotes Cell Motility and Invasion*

A. Ridley, D. Sacks, J. Mataraza, 2003, Journal of Biological Chemistry.

B Cell Receptor-induced cAMP-response Element-binding Protein Activation in B Lymphocytes Requires Novel Protein Kinase Cδ*

A. Tarakhovsky, T. Chiles, J. Mataraza, 2004, Journal of Biological Chemistry.

Recent advances in immuno‐oncology and its application to urological cancers

J. Mataraza, P. Gotwals, 2016, BJU international.

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

J. Briones, I. Flinn, U. Jaeger, 2021, Blood.

Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells.

M. Menon, D. Sacks, J. Mataraza, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Hung-Ming Wang, V. Lee, P. Lou, 2021, Clinical Cancer Research.

Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose

J. Mataraza, D. Knee, B. Wolf, 2022, Clinical and translational science.

B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase Cdelta.

A. Tarakhovsky, T. Chiles, J. Mataraza, 2004, The Journal of biological chemistry.

Identification and characterization of the Cdc42-binding site of IQGAP1.

R. Frank, D. Sacks, J. Mataraza, 2003, Biochemical and biophysical research communications.

Multiple proteins mediate IQGAP1-stimulated cell migration.

Ha-won Jeong, D. Sacks, J. Mataraza, 2007, Cellular signalling.

Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

P. Hammerman, G. Dranoff, J. Engelman, 2018, Clinical research.

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).

A. Jakubowiak, J. Ritz, S. Nikiforow, 2023, Journal of Clinical Oncology.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

J. Briones, I. Flinn, D. Blaise, 2023, Cancer discovery.

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

N. Munshi, J. Laubach, J. Ritz, 2021, Blood.